Targeted sequencing approach to identify genetic mutations in nasu-hakola disease

Intractable and Rare Diseases Research

Volumn 5, Issue 4, 2016, Pages 269-274

  Satoh, Jun ichi ^a   Yanaizu, Motoaki ^a   Tosaki, Youhei ^a   Sakai, Kenji ^a   Kino, Yoshihiro ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

DAP12; Nasu Hakola disease; Targeted sequencing; Trem2; Tyrobp

Indexed keywords

ARTICLE; AUTOSOMAL RECESSIVE DISORDER; FRAMESHIFT MUTATION; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MISSENSE MUTATION; MOLECULAR DIAGNOSIS; MUTATIONAL ANALYSIS; NASU HAKOLA DISEASE; ONCOGENE; TREM2 GENE; TYROBP GENE;

EID: 85026669160     PISSN: 21863644     EISSN: 2186361X     Source Type: Journal    
DOI: 10.5582/irdr.2016.01064     Document Type: Article

References (20)

1. Nasu T, Tsukahara Y, Terayama K. A lipid metabolic disease - "Membranous lipodystrophy" - an autopsy case demonstrating numerous peculiar membrane-structures composed of compound lipid in bone and bone marrow and various adipose tissues. Acta Pathol Jpn. 1973; 23:539-558.
2. Hakola HP. Neuropsychiatric and genetic aspects of a new hereditary disease characterized by progressive dementia and lipomembranous polycystic osteodysplasia. Acta Psychiatr Scand Suppl. 1972; 232:1-173.
3. Bianchin MM, Capella HM, Chaves DL, Steindel M, Grisard EC, Ganev GG, da Silva Júnior JP, Neto Evaldo S, Poffo MA, Walz R, Carlotti Júnior CG, Sakamoto AC. Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy -PLOSL): A dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects. Cell Mol Neurobiol. 2004; 24:1-24.
4. Satoh J, Tabunoki H, Ishida T, Yagishita S, Jinnai K, Futamura N, Kobayashi M, Toyoshima I, Yoshioka T, Enomoto K, Arai N, Arima K. Immunohistochemical characterization of microglia in Nasu-Hakola disease brains. Neuropathology. 2011; 31:363-375.
5. Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, Bianchin M, Bird T, Miranda R, Salmaggi A, Tranebjaerg L, Konttinen Y, Peltonen L. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet. 2002; 71:656-662.
6. Klünemann HH, Ridha BH, Magy L, Wherrett JR, Hemelsoet DM, Keen RW, De Bleecker JL, Rossor MN, Marienhagen J, Klein HE, Peltonen L, Paloneva J. The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology. 2005; 64:1502-1507.
7. Colonna M, Wang Y. TREM2 variants: New keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci. 2016; 17:201-207.
8. Xing J, Titus AR, Humphery MB. The TREM2-DAP12 signaling pathway in Nasu-Hakola disease: A molecular genetics perspective. Res Rep Biochem. 2015; 5:89-100.
9. Walter J. The triggering receptor expressed on myeloid cells 2: A molecular link of neuroinflammation and neurodegenerative diseases. J Biol Chem. 2016; 291:43344341.
10. Chouery E, Delague V, Bergougnoux A, Koussa S, Serre JL, Mégarbané A. Mutations in TREM2 lead to pure early-onset dementia without bone cysts. Hum Mutat. 2008; 29:E194-204.
11. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013; 368:117-127.
12. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013; 368:107-116.
13. Zemojtel T, Köhler S, Mackenroth L, et al. Effective diagnosis of genetic disease by computational phenotype analysis of the disease-associated genome. Sci Transl Med. 2014; 6:252ra123.
14. Kondo T, Takahashi K, Kohara N, Takahashi Y, Hayashi S, Takahashi H, Matsuo H, Yamazaki M, Inoue K, Miyamoto K, Yamamura T. Heterogeneity of presenile dementia with bone cysts (Nasu-Hakola disease): Three genetic forms. Neurology. 2002; 59:1105-1107.
15. Numasawa Y, Yamaura C, Ishihara S, Shintani S, Yamazaki M, Tabunoki H, Satoh JI. Nasu-Hakola disease with a splicing mutation of TREM2 in a Japanese family. Eur J Neurol. 2011; 18:1179-1183.
16. Okazaki T, Murata M, Kai M, Adachi K, Nakagawa N, Kasagi N, Matsumura W, Maegaki Y, Nanba E. Clinical diagnosis of Mendelian disorders using a comprehensive gene-targeted panel test for next-generation sequencing. Yonago Acta Med. 2016; 59:118-125.
17. Weihl CC, Baloh RH, Lee Y, Chou TF, Pittman SK, Lopate G, Allred P, Jockel-Balsarotti J, Pestronk A, Harms MB. Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis. Neuromuscul Disord. 2015; 25:289-296.
18. Kato T, Morisada N, Nagase H, Nishiyama M, Toyoshima D, Nakagawa T, Maruyama A, Fu XJ, Nozu K, Wada H, Takada S, Iijima K. Somatic mosaicism of a CDKL5 mutation identified by next-generation sequencing. Brain Dev. 2015; 37:911-915.
19. Russo CD, Di Giacomo G, Cignini P, Padula F, Mangiafico L, Mesoraca A, D'Emidio L, McCluskey MR, Paganelli A, Giorlandino C. Comparative study of aCGH and Next Generation Sequencing (NGS) for chromosomal microdeletion and microduplication screening. J Prenat Med. 2014; 8:57-69.
20. Yamamura T, Morisada N, Nozu K, Minamikawa S, Ishimori S, Toyoshima D, Ninchoji T, Yasui M, Taniguchi-Ikeda M, Morioka I, Nakanishi K, Nishio H, Iijima K. Rare renal ciliopathies in non-consanguineous families that were identified by targeted resequencing. Clin Exp Nephrol. 2016; D0I:10.1007/s10157-016-1256-x.